Who are Vantobra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tobi, Cromoglycate, Aerosolized Tobramycin or Vancomycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tobramycin-sulfate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vantobra — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vantobra (Tobramycin Sulfate) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tobramycin. Area: Metabolic.

marketed tobramycin Taste receptor type 2 member 20 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Vantobra (Tobramycin Sulfate) — Pfizer.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vantobra TARGET	Tobramycin Sulfate	Pfizer	marketed	tobramycin	Taste receptor type 2 member 20	1974-01-01
Tobi	tobramycin	Novartis	marketed		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Cromoglycate	Cromoglycate	Vishwajit Nimgaonkar, MD PhD	phase 3		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20
Aerosolized Tobramycin or Vancomycin	Aerosolized Tobramycin or Vancomycin	Wright State University	marketed	Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin)	Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-12-19 — Vantobra · 8450287 · US
2027-12-19 — Vantobra · 8101582 · US
2028-08-03 — Vantobra · 7795316 · US
2028-09-12 — Vantobra · 8869794 · US
2028-09-12 — Tobi · 8869794 · Formulation · US
2030-11-04 — Tobi · 10207066 · Formulation · US
2030-11-04 — Vantobra · 10207066 · US

Sponsor landscape (tobramycin class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vantobra — Competitive Intelligence Brief. https://druglandscape.com/ci/tobramycin-sulfate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing